Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID)
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies (NCT02822495) | Atara Biotherapeutics |
Track Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID) automatically
Every clearance here is in the API, with alerts when new ones post.